The Portfolio Lens on PE Value Creation

Every PE-backed (private equity) software company enters a hold period with a value creation plan. The plan almost always includes a revenue growth target, a margin improvement target, and a set of operational initiatives. What most plans don't include is a specific commercial diagnostic that tells you where value is already leaking before you add a dollar of new investment.

That omission is expensive. The commercial levers available in the first two years of a hold, price realization, net revenue retention (NRR) improvement, ideal customer profile (ICP) refinement, packaging restructure, are consistently the fastest path to exit premium. They're also consistently underinvested because they're harder to talk about in a board presentation than a new hire or a product roadmap.

The Real Cost

A $40M annual recurring revenue (ARR) software company entering a hold period with 17% earnings before interest, taxes, depreciation and amortization (EBITDA), 24% average discount rate, and 98% NRR is not a distressed asset. It looks fine. But compare it to the same business with 18% average discount, 107% NRR, and 23% EBITDA.

At a 10x ARR multiple, the first business exits at $400M. The second exits at around $440M on the same ARR, with a multiple premium from the NRR profile pushing it closer to $480M. The $80M gap is entirely commercial. No new product, no new markets, no M&A.

Most operating partners know this intellectually. Few have a structured program to close the gap in the first 24 months, when it's still possible to move the metrics before exit process starts.

The Framework

A commercial value creation program has three phases for your operating team.

Step 1: Commercial diagnostic in the first 60 days. Four things you need to know before you build any improvement plan: your pocket price waterfall (list to realized price), your NRR decomposed into gross retention, expansion, and contraction, your ICP concentration risk (what % of ARR is in your top 10 customers and are those customers representative of your best retention cohorts), and your sales team's ASP distribution by rep. These four diagnostics take 3-4 weeks with access to CRM and billing data.

Step 2: Sequence the interventions by value and speed. Not all commercial improvements have the same payback timeline. Price realization governance can show P&L impact within one quarter. NRR improvements take 2-3 quarters to cycle through. ICP refinement changes new logo quality but takes 4-6 quarters to show in retention metrics. Build a sequenced roadmap that shows the board early wins while the longer-cycle work matures in the background.

Step 3: Create a commercial operating cadence. Value creation doesn't happen from a one-time sprint. It requires monthly commercial reviews at the operating partner level, quarterly pricing governance meetings with the VP of Sales and CFO, and annual strategic pricing reviews tied to the exit thesis. Build the cadence, not just the intervention.

The Failure Case

A data analytics platform at $72M ARR was acquired with strong growth (32% year-over-year) and decent margins. The value creation plan focused on product investment to accelerate growth further and a sales team expansion to increase capacity.

Two years into the hold, growth had decelerated to 19% despite the sales headcount increase. The product investment hadn't produced the expected new use cases in time. Margins had compressed because the cost base grew faster than the revenue.

The operating team had never run a commercial diagnostic. They didn't know their average discount was 29%. They didn't know that their top 15 customers, representing 38% of ARR, had NRR of 89% because those accounts hadn't been managed with an expansion motion. They didn't know that two of their three sales segments had negative ROI after fully loaded customer acquisition cost (CAC).

Before: $72M ARR, 19% growth, 29% average discount, unknown NRR decomposition, expanding cost base.

After: Commercial diagnostic plus 18-month intervention: discount governance, expansion motion for top 30 accounts, two underperforming segments sunsetted. ARR grew to $98M with 24% EBITDA at exit. Original plan had projected $88M ARR at 19% margin.

What to Do This Week

Open your portfolio company's last board presentation. Count how many slides are about commercial performance metrics: discount rates, ASP trends, NRR decomposition, ICP concentration. If that number is fewer than three, your board governance is not set up to catch commercial value leakage before it compounds.

Assess Your Commercial Health to benchmark your portfolio company's commercial performance against PE-backed software peers.

Related reading: Why Your Instincts Are Wrong About Commercial Due Diligence and The Operator's Guide to EBITDA Improvement.